Observer-blind, post-marketing study to compare the safety and immunogenicity of Fluviral trivalent split virion influenza vaccine (2007-2008 season) made with new vs. aged bulk material, in adults ranging in age from 18 to 60 years.

Trial Profile

Observer-blind, post-marketing study to compare the safety and immunogenicity of Fluviral trivalent split virion influenza vaccine (2007-2008 season) made with new vs. aged bulk material, in adults ranging in age from 18 to 60 years.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs GSK 1536489A; Influenza virus vaccines
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Apr 2010 Actual number of patients added to 1000 as reported by ClinicalTrials.gov.
    • 25 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top